218. アルポート症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 30 / 薬物数 : 36 - (DrugBank : 15) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 46
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
ACE I, ATA II and Statins
Mario Negri Institute for Pharmacological Research
2004 Phase 2 NCT00309257 Italy;
ACE-inhibitor
University Hospital Goettingen
1995 - NCT02378805 Germany;
AT1-inhibitor
University Hospital Goettingen
1995 - NCT02378805 Germany;
Atrasentan
Chinook Therapeutics U.S., Inc.
2021 Phase 2 NCT04573920 Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Bardoxolone methyl
Reata Pharmaceuticals, Inc
2018 - JPRN-UMIN000032448 Japan,North America,Australia,Europe;
Reata Pharmaceuticals, Inc.
2019 Phase 3 NCT03749447 Australia;Japan;Puerto Rico;United States;
Benazepril
Shanghai Children's Hospital
2020 - ChiCTR2000036799 China;
Benazepril hydrochloride 10 milligram (mg) Tab
Shanghai Children's Hospital
2021 Phase 2 NCT04937907 China;
Benazepril, Valsartan and Fluvastatin
Mario Negri Institute for Pharmacological Research
2004 Phase 2 NCT00309257 Italy;
Delix
University Medical Center Göttingen
2012 Phase 3 EUCTR2010-024300-10-DE Germany;
Gold
Children's Hospital of Shanghai
2020 Phase 0 ChiCTR2000036550 China;
HMG-Coenzyme inhibitor (statin)
University Hospital Goettingen
1995 - NCT02378805 Germany;
Hydroxychloroquine
Shanghai Children's Hospital
2020 - ChiCTR2000036799 China;
Hydroxychloroquine Sulfate 100 milligram (mg) Tab
Shanghai Children's Hospital
2021 Phase 2 NCT04937907 China;
Lademirsen
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Lademirsen (SAR339375)
Genzyme, a Sanofi Company
2019 Phase 2 NCT02855268 Australia;Canada;China;France;Germany;Spain;United Kingdom;United States;
Paricalcitol
University Hospital Goettingen
1995 - NCT02378805 Germany;
R3R01
River 3 Renal Corp.
2022 Phase 2 NCT05267262 -
RE-021
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Travere Therapeutics, Inc.
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
RG-012
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Regulus Therapeutics Inc.
2016 Phase 2 EUCTR2016-002181-32-GB Australia;Canada;France;Germany;Spain;United Kingdom;United States;
RG012
Genzyme, a Sanofi Company
2017 Phase 1 NCT03373786 United States;
RTA 402
Reata Pharmaceuticals, Inc.
2018 Phase 2;Phase 3 EUCTR2016-004395-22-GB Australia;Canada;France;Germany;Spain;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2016-004395-22-FR Australia;Canada;France;Germany;Spain;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2016-004395-22-DE Australia;Canada;France;Germany;Spain;United Kingdom;United States;
Ramipril
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
2012 Phase 3 NCT01485978 Germany;
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2022 - NCT05133050 China;
SAR339375
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Sparsentan
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Travere Therapeutics, Inc.
2021 Phase 2 NCT05003986 Poland;Spain;United States;
Spironolactone
University Hospital Goettingen
1995 - NCT02378805 Germany;
Mario Negri Institute for Pharmacological Research
2004 Phase 2 NCT00309257 Italy;
ACE-inhibitor
University Hospital Goettingen
1995 - NCT02378805 Germany;
AT1-inhibitor
University Hospital Goettingen
1995 - NCT02378805 Germany;
Atrasentan
Chinook Therapeutics U.S., Inc.
2021 Phase 2 NCT04573920 Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States;
Bardoxolone methyl
Reata Pharmaceuticals, Inc
2018 - JPRN-UMIN000032448 Japan,North America,Australia,Europe;
Reata Pharmaceuticals, Inc.
2019 Phase 3 NCT03749447 Australia;Japan;Puerto Rico;United States;
Benazepril
Shanghai Children's Hospital
2020 - ChiCTR2000036799 China;
Benazepril hydrochloride 10 milligram (mg) Tab
Shanghai Children's Hospital
2021 Phase 2 NCT04937907 China;
Benazepril, Valsartan and Fluvastatin
Mario Negri Institute for Pharmacological Research
2004 Phase 2 NCT00309257 Italy;
Delix
University Medical Center Göttingen
2012 Phase 3 EUCTR2010-024300-10-DE Germany;
Gold
Children's Hospital of Shanghai
2020 Phase 0 ChiCTR2000036550 China;
HMG-Coenzyme inhibitor (statin)
University Hospital Goettingen
1995 - NCT02378805 Germany;
Hydroxychloroquine
Shanghai Children's Hospital
2020 - ChiCTR2000036799 China;
Hydroxychloroquine Sulfate 100 milligram (mg) Tab
Shanghai Children's Hospital
2021 Phase 2 NCT04937907 China;
Lademirsen
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Lademirsen (SAR339375)
Genzyme, a Sanofi Company
2019 Phase 2 NCT02855268 Australia;Canada;China;France;Germany;Spain;United Kingdom;United States;
Paricalcitol
University Hospital Goettingen
1995 - NCT02378805 Germany;
R3R01
River 3 Renal Corp.
2022 Phase 2 NCT05267262 -
RE-021
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Travere Therapeutics, Inc.
2021 Phase 2 EUCTR2021-000621-27-ES France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-PL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-NL France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
- Phase 2 EUCTR2021-000621-27-DE France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
RG-012
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Regulus Therapeutics Inc.
2016 Phase 2 EUCTR2016-002181-32-GB Australia;Canada;France;Germany;Spain;United Kingdom;United States;
RG012
Genzyme, a Sanofi Company
2017 Phase 1 NCT03373786 United States;
RTA 402
Reata Pharmaceuticals, Inc.
2018 Phase 2;Phase 3 EUCTR2016-004395-22-GB Australia;Canada;France;Germany;Spain;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2016-004395-22-FR Australia;Canada;France;Germany;Spain;United Kingdom;United States;
2017 Phase 2;Phase 3 EUCTR2016-004395-22-DE Australia;Canada;France;Germany;Spain;United Kingdom;United States;
Ramipril
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
2012 Phase 3 NCT01485978 Germany;
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
2022 - NCT05133050 China;
SAR339375
Genzyme Corporation
2020 Phase 2 EUCTR2019-004394-10-DE Australia;China;France;Germany;Spain;United Kingdom;United States;
Sparsentan
TRAVERE THERAPEUTICS, INC
2022 Phase 2 EUCTR2021-000621-27-IT France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
Travere Therapeutics, Inc.
2021 Phase 2 NCT05003986 Poland;Spain;United States;
Spironolactone
University Hospital Goettingen
1995 - NCT02378805 Germany;